On March 25, 2025 Convert Pharmaceuticals reported a major milestone by securing the maximum €2.5 million non-dilutive grant from the prestigious European Innovation Council (EIC) Accelerator program (Press release, Convert Pharmaceuticals, MAR 25, 2025, View Source [SID1234651401]). This competitive funding, awarded by a panel of experts, highlights the company’s innovative potential and supports its ongoing Series A investment round. After its first year of project, Convert has achieved major milestones.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The TUMAGNOSTIC trial has successfully enrolled its first patient in the Netherlands. Initial results show no signs of toxicity and a favorable pharmacokinetic profile, indicating promising safety and efficacy for the drug. Building on this momentum, the second clinical site at Erasmus MC in Rotterdam is set to open in April. Additionally, sites in Belgium and Spain are in the process of being integrated into the study.
Participation in this Phase I oncology trial requires that individuals be a minimum of 18 years. Participants must be willing to provide a new biopsy or make available genetic data from a previous one. Eligibility also depends on the presence of a specific, measurable metastatic cancer for which standard treatments aimed at improving survival have failed.
Before enrollment, the study team evaluates overall health status, including organ function through blood tests and imaging. Safety criteria exclude individuals with certain cardiac conditions and/or hepatic conditions. Additional restrictions may apply to those who have recently undergone cancer treatments, taken investigational drugs, received major surgery, or have certain cancer types, autoimmune disorders, recent vaccinations, organ transplants, or active tuberculosis.
To minimize risk during and after the study, individuals of reproductive potential—both women and men—must agree to use contraception throughout the study period and for a defined time afterwards.
To support these clinical developments, the company has also produced a new batch of its pro-drug and has identified new patentable innovations to further develop its IP portfolio.